Throughout a product’s lifecycle, health economics and outcomes research (HEOR) teams take on a number of activities to support a company’s broader market access efforts. In addition to supporting brands nearing regulatory approval, HEOR groups must be able to support teams negotiating pricing and reimbursement. Victoria Cavicchi, Research Analyst at Cutting Edge Information, discusses prioritising health economics responsibilities to impact payer pricing and formulary decisions.
https://international-pharma.com/wp-content/uploads/2015/06/Prioritizing…pdf.pdf